U.S. Businesses using ClinicalTrials.gov to market unproven and unlicensed stem cell interventions

To further public understanding of regenerative medicine, EuroStemCell has published lay summaries for all articles from the latest Regenerative Medicine special focus issue.

Go to the profile of Regenerative Medicine
Dec 05, 2017

EuroStemCell have launched a digital platform to accompany the publication of the Regenerative Medicine two-part Special Focus Issue entitled “Regenerative Medicine in Society: Interdisciplinary Perspectives”. The platform presents lay summaries of each article in the issue which are freely available to all in order to engage and educate non-experts on the key issues surrounding regenerative medicine.

You can now read the lay summary for the article entitled, “ClinicalTrials.gov, stem cells and ‘pay-to-participate’ clinical studies” from Leigh Turner [1].

Businesses in the US are registering pay-to-participate stem cell studies on ClinicalTrials.gov. A recent examination of clinical studies registered on ClinicalTrials.gov revealed multiple study listings that have not been appropriately reviewed and cleared by the FDA and are being conducted by businesses that charge study participants. To avoid the erosion of public trust in the database, studies submitted to ClinicalTrials.gov need to be properly screened before being registered and listed.

What questions & challenges are raised? What insight and direction does this give for research policies? To find out, read the full lay summary on the EuroStemCell website here: https://www.eurostemcell.org/regenerative-medicine-society/us-businesses-using-clinicaltrialsgov-market-unproven-and-unlicensed

The full original article can be accessed here: https://www.futuremedicine.com/doi/10.2217/rme-2017-0015

Read an interview with Leigh Turner on what prompted him to write the paper here: https://www.regmednet.com/users/1122-regenerative-medicine/posts/18659-pay-to-participate-stem-cells-studies-an-interview-with-leigh-turner


[1] Turner L. ClinicalTrials.gov, stem cells, and pay-to-participate clinical studies. Regen. Med. 12(6), 705–719 (2017).

Go to the profile of Regenerative Medicine

Regenerative Medicine

Journal, Future Science Group

Regenerative Medicine is an award-winning peer-reviewed journal, in print and web formats. The journal provides a forum to address the important challenges and advances in stem cell research and regenerative medicine, delivering this essential information in concise, clear and attractive article formats. Among other indexing services Regenerative Medicine is listed by MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, Science Citation Index Expanded™ (SciSearch®), Emcare, Biological Abstracts, BIOSIS Previews, Biotechnology Citation Index®, Journal Citation Reports/Science Edition®, Scopus® with an Impact Factor of 2.786 (2014). Each issue contains expertly drafted Reviews, Original Research articles, Perspectives, Editorials, topical insight from international leaders in their field, and additional added-value content. The Senior Editor of the journal is Professor Chris Mason, University College London. You can find out more about Regenerative Medicine at our website (www.future-science-group.com/journalprofile/regenerative-medicine/), where you can find the aims and scope of the journal and details of our international editorial board.

No comments yet.